Physician profile
Paul C Chukelu
NPI 1376830174
$411.33
in general payments reported to CMS, 2019-2025
10 companies · $24.80 in 2025
The $24.80 reported for 2025 was less than what a typical Emergency Medicine provider received nationally (typical 2025 total: $57.10).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $108 · 2020: $41.38 · 2021: $42.85 · 2022: $30.28 · 2023: $128 · 2024: $36.41 · 2025: $24.80.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $189.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $188.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $90.89 | 2019-2023 | |
| E.R. Squibb & Sons, L.L.C. | $86.62 | 2019-2024 | Camzyos, Eliquis |
| Janssen Pharmaceuticals, INC | $67.17 | 2021-2023 | Xarelto |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $64.77 | 2019-2025 | Lifevest |
| Novartis Pharmaceuticals Corporation | $34.59 | 2019 | |
| Pfizer INC. | $21.24 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.45 | 2020 | |
| Baxter Healthcare | $15.29 | 2023 | Hillrom - Life 2000 Ventilation System |
| Merck Sharp & Dohme LLC | $14.31 | 2023 | Dificid |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Chukelu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.